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Overview
Grattan Institute’s  March  2013  report, Australia’s  bad  drug  deal, 
showed that Australians paid more than $1 billion a year too much 
for prescription drugs.1 The problem is how the government sets 
prices. Vested interests are involved in price negotiations, there is 
no cap on expenditure, and the price cuts when a drug goes off 
patent are far smaller than in many other countries. 
The  problem  hasn’t  gone  away. Current policies  aren’t  doing  nearly  
enough to bring prices down. In December, the Commonwealth 
Government’s  “price disclosure” policy led to price cuts for seven 
generic drugs. Price disclosure tracks discounts that 
manufacturers and wholesalers give to pharmacies. Then the 
government cuts prices to reflect what pharmacies actually pay. 
The price cuts in December averaged 34 per cent. In three cases 
the cuts were big enough to reduce out-of-pocket costs for 
patients. As a result patients without a concession now save 
around $5 for each box of pills. 
That sounds like a lot. But this report compares prices after these 
cuts with prices in the UK, New Zealand and the Canadian 
province of Ontario. On average, Australian prices remain almost 
16 times higher than the best price in these three places. Our 
prices are more than 14 times higher than those in the UK.  
High prices are very costly for taxpayers and for consumers. Many 
Australians pay both through their taxes and then at the pharmacy.  
                                            
1 See Australia’s  bad  drug  deal. 
Once again, benchmarking against prices in other countries would 
get a much better deal. Of the seven drugs that had their prices 
reduced in December, patients would pay less for all of them, 
instead of just three. The out-of-pocket saving would also be much 
higher, averaging more than $21 per drug. 
The money we spend on high drug prices could be much better 
spent.  But  this  isn’t  just  about  saving  money.  Almost  one  in  10  
Australians  don’t  take  their  prescribed  medicine  because  of  the  
cost. Better prices would help more people to buy the medicine 
they need. 
The Government should take three steps to cut the extremely high 
prices we pay for generic drugs. First, it should ask the Department 
of Health to release annual international comparisons  of  Australia’s  
drug prices. Everyone would then be able to see whether we are 
getting value for money. 
Second, when the current pricing agreement expires in July next 
year, there should be one-off benchmarking to get fair market 
prices. Finally, an independent drug pricing body should be 
established to make sure prices stay low in the future. 
 
 
Poor pricing progress 
Grattan Institute 2013 2  
High prices 
Australian medicine prices are many times higher than in other 
countries. Unnecessarily inflated prices have cost patients and 
taxpayers billions of dollars.2 
In particular, Australians pay far too much for generic drugs. When 
new drugs are first introduced, they are covered by patents. In the 
main  it’s  a  sensible  system:  protection from competition allows 
high prices to reward companies for research and development.  
But once  this  protection  expires,  any  company  can  market  ‘generic  
equivalent’  drugs. Generics can usually be manufactured for a tiny 
fraction of the price the originator drug sells for and many 
companies can compete to supply them. While Australians pay 
high prices, the same drug companies are selling the same drugs 
for much less overseas. There is no reason we should pay more.3 
Our prices are high because we buy drugs in the wrong way. The 
Pharmaceutical Benefits Scheme (PBS) budget is uncapped. 
Representatives of drug companies and cabinet ministers, instead 
of independent experts, are involved in the pricing and listing of 
medicines. There are no strong incentives to make tough choices 
about putting drugs on the PBS or setting prices. Prices are set by 
negotiation, not by looking at the prices that are paid overseas. 
The result: prices that are far too high.  
                                            
2 In March 2013, Grattan Institute estimated the excess cost from high prices was 
at least $1.3 billion in 2012-13. For other discussion of high prices and the 
limitations of price reduction, see Clarke (2012). 
3 Justifications for inflated prices are discussed in detail in a previous report, our 
previous report, Australia’s  bad  drug  deal. More information on price disclosure 
and other policy settings are also in the report. 
Price disclosure 
The Commonwealth Government sets a wholesale price for each 
drug on the PBS. Patients pay pharmacists up to $36.10 (which 
includes dispensing and other fees). If the wholesale price for a 
drug  isn’t  covered  by  patients,  the  Government  pays pharmacists 
the remainder.  
But manufacturers and wholesalers often give large discounts to 
pharmacists. Before 2007, these  discounts  weren’t  taken  into  
account when the Government set prices. This meant the 
Government often paid pharmacists much more than the actual 
wholesale cost of their drugs.  
In 2007 a policy called “price disclosure” was introduced to fix this 
and cut the price of generic drugs (Figure 1 shows where price 
disclosure fits in the overall pricing process).  
Under price disclosure, drug companies collect information about 
how much pharmacies actually pay for generic medicines over a 
12-month period. Over the next six months, this information is used 
to calculate the average price after discounts. The Department of 
Health then uses this average to adjust the PBS price. 
Since 2012, price disclosure has cut the price of about 150 
medicines, sometimes by more than 50 per cent. In August this 
year the then Finance Minister announced that from mid-2014 the 
process would be sped up from 18 months to one year, saving an 
estimated $830 million over four years.4 
                                            
4 Bowen and Wong (2013). The current Government will implement the reduction 
in the price disclosure cycle and will also reduce the number of annual rounds and 
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Figure 1: The PBS pricing process 
 
 
Source: Pharmaceutical Benefits Pricing Authority (2009) 
                                                                                      
the number of days when price reductions occur, Commonwealth of Australia 
(2013). 
Price disclosure has cut the price of many drugs. In the last six 
months there have been two rounds of reductions. In August the 
prices of 39 drugs came down by an average of 26 per cent. 
December reductions bring down the prices of seven drugs by an 
average of 34 per cent.  
Nevertheless, while some progress has been made, the price 
disclosure policy has many flaws: 
x A long price disclosure process means that falling prices do not 
benefit consumers until at least a year later.  
x A loophole excludes the first month of the data collection period 
from the calculation of the reduced price. This loophole is being 
exploited, with drug companies offering  ‘specials’  on  medicines  
during  this  time,  and  pharmacists  buying  months’  worth  of  
medicine without fear of a lower profit margin later.5  
x Another  loophole  specifies  that  prices  won’t  be  reduced  if  the  
potential price reduction is less than 10 per cent. This means 
that even over cumulative rounds of reductions, many 
medications might not drop in price if the difference between 
current subsidy and the average price is relatively small.  
x Pharmacists can also receive in-kind gifts instead of direct 
discounts, such as shop fit-outs, flights or conference tickets. 
These could disguise the true purchase price of medicines, 
especially as suppliers and pharmacists adapt to the policy.  
                                            
5 For example see The Pharmacy Guild of Australia and Ranbaxy (2013) 
Pharmaceutical Benefits Advisory Committee (PBAC) 
recommends inclusion on the PBS
Pharmaceutical Benefits Pricing Authority (PBPA) 
negotiates a price with the drug company
Reviewed by the Health Minister
Reviewed by Cabinet if expenditure is expected to be 
over $10 million
Inclusion on the PBS
Price disclosure
Periodic cuts to the ex-manufacturer (wholesale) price for 
some drugs based on reporting of discounts given to 
pharmacies
over $20 million
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x The process requires extensive reporting, creating red tape for 
businesses.6 
Most  importantly,  price  disclosure  hasn’t  brought  most  prices  
anywhere near the prices paid in many other countries. There are 
still huge disparities between Australian and international prices, at 
great cost to taxpayers and patients.  
There have been calls to continue with price disclosure, to expand 
its scope, or to shorten the cycle of data collection to three 
months.7 Yet while price disclosure is better than nothing, there is 
no sign it will bring drug prices close to the low prices paid 
elsewhere any time soon. Every day this is costing taxpayers and 
patients – we need a new approach.  
Benchmarking is better 
Grattan  Institute’s  2013 report, Australia’s  bad  drug  deal, proposed 
another way to reduce the cost of pharmaceuticals on the PBS.8 It 
suggested an independent drug pricing body with a fixed budget 
and medical expertise. It also recommended sharp cuts in the price 
of new generic medicines entering the market. 
Most importantly, the new body would look at the prices paid 
elsewhere to determine what the PBS should pay. Many countries 
                                            
6 The complexity helps hide what a bad deal taxpayers get, a phenomenon 
summarised in Teles (2013):  “Policy  complexity  is valuable for those seeking to 
extract rents from government because it muddies the waters, making it hard to 
see just who is benefitting and how, and so obscuring the actual mechanism of 
political  action  that  it  is  difficult  to  mobilize  against  it”. 
7 For  example,  Philip  Clarke  has  suggested  that  there  is  scope  to  adopt  England’s  
three-month price disclosure cycle, Consumers Health Forum, et al. (2013). 
8 Duckett, et al. (2013) 
look overseas to help set prices. Twenty-five out of 27 EU 
member countries, along with Canada, New Zealand and Japan, 
use some form of benchmarking.9 The UK is often used in these 
comparisons, with 11 countries using it as a benchmark.  
The model proposed in Australia’s  bad  drug  deal would have an 
independent pricing authority set a price (based on an international 
benchmark) and allow many drug companies to sell at that price. 
This model would still allow choice for consumers, just as the 
current system does – any manufacturer would still be free to sell 
the drug.   
To contrast benchmarking with price disclosure, we compared 
prices in the UK, New Zealand and Canada’s  largest  province, 
Ontario. We only looked at drugs that have had their prices cut in 
the December round of price disclosure reductions.10 Even after 
these  cuts,  Australia’s  prices  are an average of 15.8 times 
higher.11 The  PBS  doesn’t  have  the  lowest price for any of these 
drugs. 
These comparisons are conservative. Most countries benchmark 
against many others: Germany, for instance, looks at the prices 
paid in 15 different countries before setting its own.12 We only 
looked at the best prices in three jurisdictions. Furthermore, where 
                                            
9 Espin, et al. (2011); Ruggeri and Nolte (2013). Many other countries outside the 
EU also use reference pricing. It has a varying degree of influence on pricing in 
different countries. We propose that it be at the centre of pricing decisions. 
10 This comparison uses ex-manufacturer prices (before retail mark-ups and 
dispensing fees). 
11 All comparisons are based on a nominal dose. See the methodological 
appendix for more information. 
12  Espin, et al. (2011) 
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there were multiple prices within NZ, the UK or Ontario, we always 
chose the most expensive one for comparison.   
As Figure 2 shows, even this conservative benchmarking dwarfs 
the savings from price disclosure. The height of the bars shows 
how many times greater the price for a drug is here compared to 
the lowest price in the UK, New Zealand or Ontario (using 
wholesale prices). The lighter bars show how many times more 
expensive our prices were before the price disclosure cuts. The 
darker bars show the situation now.  
Even after price disclosure cuts, our prices are a very bad deal. 
For three of the seven drug doses we looked at, Australia’s  prices  
are well over 20 times higher than the best price in the UK, New 
Zealand or Ontario.  
 
 
 
 
 
 
Box 1: Atorvastatin – still costing far too much 
Atorvastatin (formerly sold only under the brand name Lipitor) is a 
drug that lowers cholesterol. It is one of the most commonly 
prescribed drugs, with nearly 10 million scripts issued each year.13  
On 1 December the ex-manufacturer price of a box of 30 40mg 
pills falls from $38.69 to $19.32. This sounds like a big drop, but 
the ex-manufacturer price in the UK is the equivalent of $2.84. In 
New Zealand it is only $2.01 cents. 
For this drug alone, the massive premium paid in Australia costs 
taxpayers tens of millions of dollars a year. Many Australians are 
paying for these high prices twice – once through their taxes and 
then again at the pharmacy.  
After pharmacy mark-ups the December price reduction will save 
patients without a concession about $7 per box of pills.14 But if we 
had  the  UK’s  wholesale  prices,  the  saving  would  be  up to almost 
$19 greater, and almost $20 more with New Zealand’s wholesale 
prices. Patient savings from benchmarking are discussed further 
below. 
 
                                            
13 Department of Health and Ageing (2013)  
14 All out-of-pocket cost comparisons are for non-concessional patients above the 
Safety Net threshold. See the appendix for more detail on our assumptions. 
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Figure 2: PBS prices as multiples of the lowest price in NZ, UK or 
Ontario before and after price reductions 
 
Notes: Based on nominal doses. Australian prices before reductions are approximate. See 
methodological appendix for more detail.  
Source: Grattan Institute  
 
Not  just  beaten  by  “third  world”  New  Zealand 
There have been criticisms of comparing of Australian and New 
Zealand drug prices. In response to our report, Brendan Shaw, 
CEO of pharmaceutical industry group Medicines Australia, said 
that adopting drug pricing policies from New Zealand would give 
Australia   the   health   system   of   a   “third  world   country”.15 He also 
claimed  that  New  Zealand  is  a  “basket  case”  in  terms  of  access  to  
medicine, and is the last place we should be looking for ideas.  
Dr  Shaw’s  criticisms  are  mostly  related  to  patented  medications, 
which are not the subject of this report.16 New Zealand does 
have a more limited range of subsidised drugs than Australia. Its 
low prices are also partly due to a sole-supplier model, which we 
don’t   recommend.   But   these   criticisms   are   a   distraction   from  
Australia’s   sky-high   prices.   It’s   not   just   New   Zealand   that has 
much better prices. Many countries that have similar access to 
the wide range of subsidised drugs available in Australia also 
have fairer prices. 
To prove this, we did a second comparison against the UK and 
Ontario. Neither has a sole-supplier model. According to the 
same reports used to criticise access to medicines in New 
Zealand, over the last five years the number of subsidised drugs 
                                            
15 Shaw, Brendan. Pressure on Market Access in Australia, Speech to Medicines 
New Zealand Conference, 9-oct-2013, Auckland.  
16 Patented medicines are not subject to price disclosure. Because any company 
can produce and sell generic drugs, internationally competitive prices are not a 
real risk to supply. If a company refuses to sell for a price similar to prices that 
are profitable overseas, another company is very likely to take the opportunity to 
do so. 
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in the UK is 14 per cent higher than in Australia.17 Recent 
Ontario data is not available, but Australia had a similar level of 
drug availability to Ontario for the three years to 2010.18 
Our wholesale prices are 14.5 times   higher   than   the  UK’s   and  
more than double Ontario’s. As just one example, the breast 
cancer drug anastrozole (Arimidex) costs $92 for a box of 30 
1mg tablets on the PBS but a mere $3.30 in the UK. These are 
wholesale prices, but high prices often flow through both to 
patients at the pharmacy and to taxpayers, as detailed below. 
As Figure 3 shows, while New  Zealand’s  prices  are   the   lowest,  
we still lag far behind the UK and Ontario. Australia’s  small size 
is no excuse for the prices we pay – both New Zealand and 
Ontario are much smaller markets (with populations of around 
4.5 million and 13 million). 
                                            
17 Based on Canadian, pharmaceutical industry-funded reports cited by Dr Shaw 
to characterise access to drugs in New Zealand, Shaw (2013). The measure of 
access is the proportion of the drugs available in Canada that have a public 
subsidy in other countries. On this measure, access in the UK is comparable to 
Australia. However, it is not a good measure of access to medicines. Firstly, the 
list  of  drugs  in  different  countries  varies,  so  no  country  has  all  of  Canada’s  drugs,  
and some subsidised  drugs  in  other  counties  are  excluded.  Secondly,  it  doesn’t  
take account of how often drugs are used. Finally, price is a barrier to access 
and this measure ignores costs to consumers. On this measure, in the five  
years to 2011-12 Australia only had lower  ‘access’  than  the  UK  in  2011-12, by 
11% (the full range of variation is 70%), Wyatt Healthcare (2007-2012).  
18 Wyatt Healthcare (2007-2012) 
Figure 3: PBS prices as multiples of NZ, UK and Ontario prices, 
following December price disclosure reductions 
 
 
Note: Based on nominal doses 
Source: Grattan Institute 
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High costs for patients 
High prices cost patients as well as taxpayers. In fact, patients 
pay a growing share of the cost of drugs on the PBS, rising from 
23 to 30 per cent in the six years to 2010-11.19 The results of high 
prices are serious. An estimated nine per  cent  of  Australians  don’t  
fill their medicine prescriptions because of the cost.20  
Price disclosure is having some impact. It is bringing the price of 
some drugs below $36.10, the maximum price paid by patients 
who  don’t  have  a  concession and are below the Safety Net 
threshold. For the doses we compared, the December reductions 
range from around $2 to $7 a pack, for three different drugs.21  
Yet benchmarking would do much more. It would cut out-of-
pocket costs for all seven drugs, not just three. The savings are 
much bigger, averaging up to nearly $22.  
The impact on an individual can be big, especially if they take 
several drugs. Ivan (not a real person) is a 55-year old who takes 
atorvastatin for high cholesterol and venlafaxine for mild 
depression. On these drugs alone, benchmarking could save him 
up to almost $350 a year.22 
                                            
19 Includes payments at and below copayment threshold, Harvey (Forthcoming). 
20 ABS (2012). 
21 All calculations refer to non-concessional patients below the Safety Net 
threshold. See the appendix for more detail. 
22 At  current  prices  Ivan’s  costs  are  below  the  Safety  Net,  see  the  appendix. 
Figure 4: Savings to non-concessional patients from price 
disclosure and benchmarking 
 
Note: Savings are for non-concession patients above the Safety Net. Based on nominal 
doses. See appendix for more detail. 
Source: Grattan Institute 
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A better policy for a better deal  
Benchmarking against the best international prices is a much 
better policy than price disclosure.  
x It is faster, as benchmarking does not have the lengthy data 
collection period used in price disclosure 
x It is less administratively complex for both government and 
drug companies, and would close the loopholes that exist in 
price disclosure 
x It can easily be applied to a larger number of drugs, including 
drugs that are not generics 
x Most importantly, benchmarking would result in far greater 
savings for the government and patients 
Price disclosure is bringing down the excessively high prices of 
Australian generic medicines. But we would do a lot better if we 
compared our prices against the lowest prices in comparable 
countries. The flawed price disclosure process will not bring down 
costs far enough, or fast enough. There are no prizes for having 
the  ‘most  improved’  price – not when the price started out being 
astronomically high. 
By contrast, benchmarking would allow huge reductions in price, 
while maintaining choice and certainty of supply.23  
                                            
23 For more information, see Duckett, et al. (2013) 
As a first step, the Commonwealth Government should ask the 
Health Department to publish price comparisons with several 
countries each year.24 Even supporters of current polices should 
agree with more transparency and accountability about how 
Australia’s  prices compare. 
There is also an opportunity to do a one-off price reduction in mid-
2014,  when  the  Government’s  commitment  to  current  pricing  
arrangements expires.25 In the longer-term, an independent 
pricing body should be established, as our previous report 
proposed. In practice, benchmarking would need to leave a buffer 
for exchange rate fluctuations. But our estimates of savings are 
very conservative and this buffer is unlikely to reduce them by 
much. 
Better prices would significantly reduce income for community 
pharmacies.26 This is a real challenge. But there are ways to 
address it without giving up on fair prices. One option could be 
expanding the services that pharmacists can provide, giving them 
new sources of income.27 Other options are direct, transparent 
subsidies to community pharmacies in locations where viability 
may be an issue, or taking steps to make the sector more 
                                            
24 We suggest, at a minimum, that the comparators for this report be included. 
25 Pricing is governed by a Memorandum of Understanding between the 
Government and the pharmaceuticals industry group Medicines Australia.  
26 Primarily from the windfall profits from paying prices below the government 
approved ex-manufacturer price, and partly because pharmacies charge a mark-
up which increases with drug prices, their income will decline when prices fall. 
Lower prices would also have a small financial impact on hospitals that dispense 
drugs using PBS prices. 
27 We propose this in the context of rural workforce shortages in a previous 
report, Access all areas. 
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competitive and efficient. But these costs need to be weighed 
against the huge benefits of getting a better deal on drug prices. 
With nearly 200 million individual scripts a year filled, lower prices 
on essential medicines would create big savings for patients. It 
would also free up a significant proportion of the health budget. 
Advocates of price disclosure might argue that it will eventually 
achieve the same price as benchmarking. For this to be true, 
manufacturers would have to discount to international benchmark 
prices. Then those discounts would need to be fully captured by 
price disclosure reporting. Even then, patients and taxpayers 
would keep paying higher prices while price disclosure reporting 
and analysis is carried out. 
High drug prices waste millions of dollars  a  day.  This  doesn’t  just  
put pressure on the health budget and on taxpayers, it means 
more  people  can’t  afford  to  buy  medicine  that  a doctor has 
prescribed. There is a much better way to set drug prices. To get 
a fair deal on medicines, Australia needs to keep up with the rest 
of the world. 
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Methodological appendix
Data about price reductions was sourced from the Pharmaceutical 
Benefits Scheme website. Information on volume of prescriptions 
was generated through the PBS item reports. International pricing 
data were retrieved from the following websites: 
Canada  https://www.healthinfo.moh.gov.on.ca/formulary/ 
UK http://psnc.org.uk/funding-and-statistics/structure-of-
pharmacy-funding/drug-tariff-reimbursement/ 
NZ http://www.pharmac.govt.nz/Schedule 
 
When multiple prices were available overseas, we chose the more 
expensive option. A price reduction occurs on all forms of a drug – 
for example, a 20 per cent reduction on atorvastatin will apply to 
the prices for a box of 10, 20, 40 and 80mg tablets. We made 
comparisons  on  one  dose  of  medicine  only,  a  ‘nominal  dose’  – for 
example, a pack of 30 40mg Atorvastatin tablets. Prices were 
adjusted for pack size and dose if necessary. The average 
exchange rate for the year to the end of September was used: 
NZ$1.21; £0.64; CA$1.01. Two and three-year averages are 
higher (resulting in greater savings) than the values we used. 
Comparisons involving multiples of the benchmark price do not 
include pharmacy mark-ups, but apply only to the ex-
manufacturer price.  
When calculating out-of-pocket savings for patients, we added 
pharmacy mark-ups. Pharmacy mark-ups were calculated using 
the fees set out in the Fifth Community Pharmacy Agreement.28 
These calculations are approximate because we assumed that 
only the Pharmacy Mark-up and the Ready Prepared Fee were 
applied. All out-of-pocket cost comparisons are for patients that 
do not have concessions and are above the Safety Net threshold. 
For the fictitious example of Ivan the daily doses are: atorvastatin, 
40mg; and venlafaxine, 37.5mg. Currently, the total annual out-of-
pocket cost of these drugs (using the same assumptions 
described above) is $567, well below the Safety Net threshold of 
$1,390.60. With benchmarking, out-of-pocket costs would fall to 
$222.29 
  
                                            
28 Department of Health and Ageing and the Pharmacy Guild of Australia (2010) 
29 These figures represent average annual expenditure and savings (pack sizes, 
such as 30 pills, do not exactly align with the length of months or years). 
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